SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00830245

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

To assess the efficacy and safety of erlotinib for non-small cell lung cancer patients with leptomeningeal carcinomatosis

NCT00830245 Leptomeningeal Carcinomatosis Non-small Cell Lung Cancer
MeSH:Lung Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma Meningeal Carcinomatosis
HPO:Carcinoma Neoplasm of the lung Non-small cell lung carcinoma

1 Interventions

Name: Erlotinib

Description: Erlotinib 150mg/day
Type: Drug
Group Labels: 1

Erlotinib


Primary Outcomes

Measure: Overall survival

Time: 1 year

Secondary Outcomes

Measure: Cytology negative conversion rate

Time: 1 month, 2 months, 3 months, 4 months

Measure: Neurologic symptom improvement

Time: 1 month, 2 months, 3 months, 4 months

Measure: Response rate (extra-cranial disease)

Time: 2 months, 4 months

Measure: Response rate (brain)

Time: 2 months, 4 months

Measure: Quality of life

Time: 1 month, 2 months, 3 months, 4 months

Measure: Toxicities

Time: 1 month, 2 months, 3 months, 4 months

Measure: Prognostic factors

Time: N-A

Purpose: Treatment

Allocation: Non-Randomized

Single Group Assignment


There is one SNP

SNPs


1 L858R

Inclusion Criteria: 1. Age >18 2. Histologically or pathologically proven non-small cell lung cancer (NSCLC) 3. Leptomeningeal carcinomatosis confirmed by CSF cytology 4. A patients with EGFR mutation (including exon 19 deletion, L858R) 5. ECOG performance status 0-3 6. Expected life time more than at least 4 weeks 7. --- L858R ---

A patient who refused to sign the informed consent Inclusion Criteria: 1. Age >18 2. Histologically or pathologically proven non-small cell lung cancer (NSCLC) 3. Leptomeningeal carcinomatosis confirmed by CSF cytology 4. A patients with EGFR mutation (including exon 19 deletion, L858R) 5. ECOG performance status 0-3 6. Expected life time more than at least 4 weeks 7. --- L858R ---



HPO Nodes


HPO: